Fidelity International
BCAX

Fidelity International’s Bicara Therapeutics BCAX Stock Holding History

Fidelity International’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Sell
62,174
-617,730
-91% -$13.8M ﹤0.01% 794
2026
Q1 		$13.5M Sell
679,904
-78,589
-10% -$1.35M 0.01% 548
2025
Q4 		$12.8M Sell
758,493
-45,260
-6% -$773K 0.01% 548
2025
Q3 		$12.7M Sell
803,753
-210,100
-21% -$2.35M 0.01% 537
2025
Q2 		$9.42M Hold
1,013,853
– – 0.01% 551
2025
Q1 		$13.2M Hold
1,013,853
– – 0.01% 491
2024
Q4 		$17.7M Hold
1,013,853
– – 0.02% 462
2024
Q3 		$25.8M Buy
+1,013,853
New +$25.9M 0.02% 425

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity International's BCAX Position: Q2 2026 in Review

Fidelity International reduced its Bicara Therapeutics (BCAX) stake by 91% in Q2 2026, selling an estimated $13.8M and leaving 62,174 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #794.

Fidelity International first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. The position peaked at $25.8M in Q3 2024. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Fidelity International held 62,174 shares of Bicara Therapeutics worth $1.85M as of Q2 2026.
  • Fidelity International sold 617,730 Bicara Therapeutics shares in Q2 2026, an estimated $13.8M.
  • Bicara Therapeutics made up ﹤0.01% of Fidelity International's portfolio in Q2 2026, its #794 holding.
  • Fidelity International first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Fidelity International's Bicara Therapeutics position peaked at $25.8M in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.